( ndreds of scientists atBristol- Myers ...)Data Available from Erbitux Phase III Study in First-Line Treatment,of Advanced Pancreatic Cancer,Health

Bristol-Myers Squibb is a global pharmaceutical and related health care products company whose mission is to extend and enhance human life.

This press release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995, regarding the development and commercialization of an investigational compound. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change any of them, and could cause actual outcomes and results to differ materially from current expectations. No forward-looking statement can be guaranteed. Forward-looking statements in the press release should be evaluated together with the many uncertainties that affect Bristol-Myers Squibb's business, particularly those identified in the cautionary factors discussion in Bristol-Myers Squibb's Annual Report on Form 10-K for the year ended December 31, 2006, its Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K. Bristol-Myers Squibb undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.

CONTACT: Rebecca Gregory, Corporate Communications of ImClone SystemsIncorporated, +1-646-638-5058, ; or Media, Madeline Malia,+1-609-252-3347, , or Tony Plohoros, +1-609-252-7938,, or Investors, John Elicker, +1-212-546-3775,, all of Bristol-Myers Squibb media@imclone.com Madeline.Malia@bms.com tony.plohoros@bms.com John.Elicke
'"/>